The study, primarily authored by Dr. Foley, examines the efficacy and safety of Injectable Discogenic Cell Therapy.
Dr. Foley holds several professional appointments including director of complex spine surgery at Semmes-Murphey Neurologic and Spine Institute and professor of neurosurgery at the University of Tennessee Health Science Center, both in Memphis.
DiscGenics is a spine therapeutics company focused on stem cell and tissue engineering treatments for degenerative disc disease.
More Articles on Spine:
Mercy Medical Center – Des Moines Earns Blue Distinction
10 Statistics on Reoperation After Spine Surgery for Disc Herniation
Infection Rate Associated With Irradiated Allograft Bone
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
